Fundamentals of Pharmaceutical and Biologics Regulations, Fourth Edition
Author: Gloria Hall
Publisher:
Published: 2021-07-23
Total Pages:
ISBN-13: 9781947493698
DOWNLOAD EBOOK →Author: Gloria Hall
Publisher:
Published: 2021-07-23
Total Pages:
ISBN-13: 9781947493698
DOWNLOAD EBOOK →Author: Regulatory Affairs Professionals Society
Publisher:
Published: 2023-05
Total Pages: 0
ISBN-13: 9781947493865
DOWNLOAD EBOOK →Author: Gloria Hall
Publisher:
Published: 2020-07-29
Total Pages:
ISBN-13: 9781947493513
DOWNLOAD EBOOK →Author: Pamela A. Jones
Publisher:
Published: 2019
Total Pages:
ISBN-13: 9781947493315
DOWNLOAD EBOOK →Author: Gloria Hall
Publisher:
Published: 2020-03-06
Total Pages:
ISBN-13: 9781947493414
DOWNLOAD EBOOK →Author: Rebecca Sheets
Publisher: Academic Press
Published: 2017-12-13
Total Pages: 450
ISBN-13: 0128094435
DOWNLOAD EBOOK →Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines serves as an introduction to the international regulatory arena in which biologicals are developed and offers an overview of the processes and insight into the scientific concepts underpinning global regulations. This book will provide multiple levels of readership with guidance on basic concepts, a detailed look at regulatory challenges, and practical insight into how regulators consider regulatory science and regulatory process issues across various regions. With numerous case studies, learning activities, and real-world examples across several classes of biotechnological products, this book is a valuable and comprehensive resource for graduate students, professors, regulatory officials, and industry scientists working with biologicals. Provides a broad overview and introduction to the regulatory processes, from product development pathways, through clinical trials and product development stages and beyond Includes FDA, EMA, ICH, and WHO recommendations and guidelines so readers can compare and contrast the different regulatory regions with their expectations and understand why they are different Contains chapters on some of the exceptions to the process including how biosimilars and in vitro diagnostics are regulated Includes numerous case studies, learning activities, and real-world examples across several classes of biotechnological products
Author: Joanne S. Hawana
Publisher:
Published: 2018
Total Pages: 185
ISBN-13:
DOWNLOAD EBOOK →Promotion of FDA-Regulated Medical Products is the update of the 2013 publication, FDA requirements for prescription drug promotion, by John Driscoll.
Author: Maria Cristina Galli
Publisher: Springer Nature
Published: 2023-08-01
Total Pages: 243
ISBN-13: 3031345673
DOWNLOAD EBOOK →This book discusses the different regulatory pathways for Advanced Therapy Medicinal Products implemented by national agencies in North and South America, Europe and Asia and by international bodies in the effort of international harmonization. This book represents an update of the first edition, as it covers regulatory novelties and accumulated experience in the regions already addressed. In addition, this new edition offers a wider international perspective: new chapters are included covering Advanced Therapy Medicinal Products regulations in India, Malaysia, Spain and Thailand, the European Pharmacopoeia texts for gene therapy medicinal products as well as international harmonization programs. Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure and therapeutic use of these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of Advanced Therapy Medicinal Products in the areas of product quality, pharmacology and toxicology, clinical trial design and HTA pathways, as well as pertinent ‘must-know’ guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: a Global Perspective is part of the American Society of Gene & Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals.
Author: Gloria Hall
Publisher:
Published: 2020-12-04
Total Pages:
ISBN-13: 9781947493551
DOWNLOAD EBOOK →Author: John Geigert
Publisher: Springer
Published: 2019-05-08
Total Pages: 426
ISBN-13: 3030137546
DOWNLOAD EBOOK →Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.